Drugs / PENBRAYATM
last change Aug 2025 re-read 2 minutes ago

PENBRAYATM

Developed for
meningococcal infection
Investigated by
Sanofi Pasteur, a Sanofi Company

Trials 1 · a red edge is where a trial was stopped

202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT06128733 Oct 2023 → Aug 2025 meningococcal infection Sanofi Pasteur, a Sanofi Company Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as PENBRAYATM PENBRAYATMNCT06128733